Recently, China has successfully developed and clinically deployed its first domestically produced percutaneous ventricular assist device (pVAD), marking a significant breakthrough in the field of high-end medical devices. Dubbed ‘HeartBridge,’ this minimally invasive artificial heart is independently developed by a Chinese research team. It is implanted via the femoral artery without the need for open-chest surgery, significantly reducing patient trauma and postoperative recovery time. The device is primarily designed to provide short-term circulatory support for patients with acute heart failure or high-risk cardiac conditions—offering critical life support during heart surgery, patient transport, or while awaiting heart transplantation. Compared to traditional external artificial hearts, its percutaneous design greatly lowers infection risks and enhances patient mobility. The first-in-human clinical trial has already been completed, with the patient showing stable vital signs and good recovery. This achievement not only fills a domestic technological gap but also breaks foreign monopolies, paving the way for broader access to advanced cardiac care and accelerating China’s innovation in high-end medical equipment.
近日，中国成功研发并临床应用了首款国产介入式人工心脏，标志着我国在高端医疗器械领域取得重大突破。这款名为‘心擎’的介入式心室辅助装置（pVAD），由国内科研团队自主研发，采用微创介入技术，通过股动脉植入，无需开胸手术，大大降低了患者创伤和术后恢复时间。该设备主要用于急性心力衰竭或高危心脏病患者的短期循环支持，可在心脏手术、转运或等待心脏移植期间提供关键生命支持。与传统体外人工心脏相比，介入式设计显著减少了感染风险，并提升了患者活动自由度。目前，该产品已完成首例人体临床试验，患者术后恢复良好，各项指标稳定。这一成果不仅填补了国内在该领域的空白，也打破了国外技术垄断，有望未来惠及更多心血管重症患者，推动我国高端医疗装备自主创新进程。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/5130.html